ELAN Trial Summary: Early vs. Late DOAC Initiation After Ischemic Stroke in Atrial Fibrillation
Primary Finding
The ELAN trial demonstrated that early initiation of direct oral anticoagulants (DOACs) in patients with atrial fibrillation and acute ischemic stroke is both safe and effective, with early treatment showing a net clinical benefit over guideline-based delayed initiation. 1, 2
Trial Design and Patient Selection
ELAN was an international, multicenter, randomized controlled trial (1:1 allocation) with assessor-blinded outcome adjudication conducted across 103 sites in 15 countries between November 2017 and September 2022. 1, 2
The trial enrolled 2013 patients with atrial fibrillation-associated acute ischemic stroke who were eligible for DOAC therapy. 2
Patients were selected using neuroimaging criteria to stratify stroke severity by infarct size (minor, moderate, or major), which determined the timing windows for both treatment arms. 1
Key exclusions included patients already on therapeutic anticoagulation at stroke onset and those with severe hemorrhagic transformation of the ischemic infarct. 2
Treatment Arms and Timing Protocol
Early Treatment Arm:
- DOAC initiation within 48 hours for minor or moderate stroke 1
- DOAC initiation at day 6-7 following major stroke 1
Late Treatment Arm (Guideline-Based):
- DOAC initiation after day 3-4 following minor stroke 1
- DOAC initiation after day 6-7 following moderate stroke 1
- DOAC initiation after day 12-14 following major stroke 1
Primary Outcome Results
The primary composite outcome (symptomatic intracranial hemorrhage, major extracranial bleeding, recurrent ischemic stroke, systemic embolism, or vascular death at 30 days) occurred in 3.3% of the early treatment group versus 4.8% in the late treatment group. 3
Early DOAC initiation was associated with lower event rates across all stroke severity categories, with the most pronounced benefit in patients who did not receive acute reperfusion therapy (adjusted odds ratio 0.69,95% CI 0.36-1.28). 3
Net Clinical Benefit Analysis
The net clinical benefit of early treatment ranged from 1.72 to 1.73 weighted events prevented per 100 participants at 30 days (95% CI 0.06-3.40 to -0.63 to 3.98, depending on the weighting scheme for intracranial hemorrhage severity). 2
At 90 days, the net clinical benefit increased to 2.14 to 2.16 weighted events prevented per 100 participants (95% CI 0.30-3.87 to -0.26 to 4.41). 2
The analysis accounted for the differential clinical impact of bleeding versus ischemic events using established weighting schemes, with intracranial hemorrhage weighted 1.5 to 3.3 times more heavily than ischemic events. 2
Safety Profile
No significant safety concerns emerged with early DOAC initiation, with numerically lower rates of the primary composite outcome in the early treatment group across all patient subgroups. 3
Prior acute reperfusion therapy (intravenous thrombolysis, endovascular treatment, or both) did not modify the treatment effect of early versus late DOAC initiation. 3
In patients who received intravenous thrombolysis, event rates were 3% in the early group versus 2% in the late group (adjusted odds ratio 1.52,95% CI 0.52-4.84), showing no increased harm. 3
Clinical Implications
ELAN provides high-quality randomized evidence supporting earlier DOAC initiation than traditional guideline-based timing, particularly when patients are selected by neuroimaging assessment of infarct size. 1, 2
The trial's neuroimaging-based selection strategy allowed for individualized timing based on stroke severity while maintaining safety, representing a more nuanced approach than fixed time-based protocols. 1
The findings suggest that the traditional delays recommended in older guidelines (based on warfarin and heparin data) may be unnecessarily conservative for DOACs, which have a more favorable intracranial hemorrhage profile. 2, 4
Important Caveats
While the point estimates favor early treatment, the confidence intervals for net clinical benefit include the possibility of no benefit or small net harm, though the overall trend strongly suggests benefit. 2
The trial excluded patients with severe hemorrhagic transformation, so these findings do not apply to that high-risk subgroup. 2
The ELAN protocol still incorporated a 6-7 day delay for major strokes even in the "early" arm, recognizing the higher hemorrhagic risk in large infarcts. 1